Rezdiffra (Resmetirom) Employer and ICHRA Coverage Navigation

What Rezdiffra Is and Why Coverage Is Complicated

Rezdiffra (resmetirom) received FDA approval on March 14, 2024, making it the first approved pharmacotherapy for metabolic dysfunction-associated steatohepatitis (MASH) with liver fibrosis staged F2 or F3 [1]. It works as a liver-directed thyroid hormone receptor beta (THR-β) agonist, selectively reducing hepatic lipid accumulation without the systemic thyroid side effects seen with earlier compounds [2].

The Approval That Changed the Field

The approval was based on the MAESTRO-NASH trial (N=966), a Phase 3 study published in the New England Journal of Medicine. At 52 weeks, resmetirom 80 mg achieved MASH resolution without worsening fibrosis in 25.9% of patients vs. 14.2% placebo (P<0.001), and fibrosis improvement of at least one stage in 25.9% vs. 9.7% placebo (P<0.001) [3]. These are the largest fibrosis improvement rates seen in any MASH pharmacotherapy trial to date.

Why Payers Push Back

Because Rezdiffra launched mid-2024, most employer plan formularies were already locked for 2024 to 2025. A drug with an annual WAC near $47,400 automatically triggers utilization management. Payers typically require prior authorization (PA), proof of biopsy-confirmed or noninvasive test-confirmed F2, F3 fibrosis, documented lifestyle intervention failure, and sometimes step therapy through weight-loss agents first [4].

The FDA label specifies use in adults with noncirrhotic MASH with moderate-to-advanced hepatic fibrosis (F2 or F3) as characterized by liver biopsy or noninvasive testing [1]. That specificity helps PA approvals when documentation is complete.

Understanding Your Employer Plan's Formulary Tier

Employer-sponsored plans fall under ERISA (Employee Retirement Income Security Act), which gives self-funded plans broad discretion in formulary design. Fully insured small-group plans follow state mandates, which vary widely [5].

Where Rezdiffra Sits on Most Formularies

In 2026, most large pharmacy benefit managers (PBMs) place Rezdiffra on Tier 4 or Tier 5 (specialty), with a coinsurance ranging from 20% to 40% after deductible. A 20% coinsurance on a $47,400 annual cost produces a $9,480 patient liability before copay assistance. Some plans have carved Rezdiffra to a non-formulary status, requiring a full formulary exception before any coverage applies [4].

How to Check Your Specific Formulary

1. Log in to your health plan's member portal and search the drug formulary by brand name "Rezdiffra" or generic name "resmetirom."
2. Call the member services number on your insurance card. Ask specifically: "Is resmetirom on formulary, what tier, and what prior authorization criteria apply?"
3. Ask your prescribing hepatologist or gastroenterologist to run a benefits investigation through their specialty pharmacy. Most specialty pharmacies do this at no charge.

Specialty Pharmacy Dispensing

Rezdiffra is distributed through a limited specialty pharmacy network. Madrigal contracts with specific specialty pharmacies, so patients cannot fill this at a retail chain in most cases. Your physician's office or HealthRX care coordinator can confirm which specialty pharmacies are in-network for your plan [1].

Prior Authorization: What You Need to Win Approval

A complete PA submission prevents the most common cause of denial: missing documentation. The FDA label and MAESTRO-NASH trial entry criteria define what payers typically require [3].

Required Documentation Checklist

• Diagnosis code K76.0 (fatty liver, not elsewhere classified) or K75.81 (nonalcoholic steatohepatitis) with fibrosis stage F2 or F3
• Liver biopsy report or validated noninvasive fibrosis test result (e.g., FibroScan with LSM ≥8.2 kPa, or FIB-4 score with confirmatory imaging)
• Current body weight and BMI (determines 80 mg vs. 100 mg dosing)
• Documentation that the patient does not have cirrhosis (F4 is outside the labeled indication) [1]
• Evidence of lifestyle intervention and, if applicable, GLP-1 receptor agonist history
• Prescriber attestation that Rezdiffra is medically necessary

What Happens After Submission

Standard PA turnaround is 3 to 5 business days. Urgent PA (for patients with rapidly progressing fibrosis) can be 24 to 72 hours. If the initial PA is denied, you have the right to an internal appeal under the ACA, and for ERISA plans, an external review if the internal appeal fails [5]. The American Association for the Study of Liver Diseases (AASLD) 2023 practice guidance supports pharmacotherapy for MASH with significant fibrosis, which strengthens medical necessity arguments in appeals [6].

Formulary Exception and Step Therapy Override

If Rezdiffra is non-formulary or requires step therapy, a formulary exception request can bypass those barriers.

Building the Exception Letter

An effective exception letter contains four elements: (1) the clinical evidence from MAESTRO-NASH showing statistically significant fibrosis improvement [3]; (2) the FDA label confirming this is the only approved drug for this indication [1]; (3) a statement that no therapeutically equivalent alternative exists at a lower tier (no other drug is FDA-approved for MASH as of 2026); and (4) patient-specific clinical data showing F2, F3 fibrosis with disease progression risk.

The AASLD 2023 guidance states: "Patients with MASH and significant fibrosis (stage F2, F3) are at the highest risk for disease progression to cirrhosis and should be prioritized for pharmacologic treatment" [6]. Quoting guideline language directly in exception letters increases approval rates.

Step Therapy Overrides

Some plans require documented failure of a GLP-1 receptor agonist (e.g., semaglutide) before approving Rezdiffra. The American Liver Foundation notes that while GLP-1s show promise in MASH, no GLP-1 has FDA approval for MASH with fibrosis as of 2026, making a step therapy requirement clinically questionable [7]. Your prescriber can cite this in an override request. Several states have enacted step therapy reform laws requiring insurers to grant overrides when the required drug is not FDA-approved for the patient's condition.

ICHRA Coverage Navigation

An Individual Coverage Health Reimbursement Arrangement (ICHRA) lets employers reimburse employees for individually purchased health insurance and qualified medical expenses. The IRS defines qualified medical expenses under Section 213(d) [8].

How ICHRA Works for Rezdiffra

Under an ICHRA, the employer sets a monthly reimbursement allowance. Employees purchase an individual market plan (on or off the ACA exchange), then submit covered expenses for reimbursement. Rezdiffra is reimbursable through ICHRA if it is covered under the individual plan the employee chose [8].

The critical step: when selecting an individual market plan under ICHRA, verify Rezdiffra's formulary status on that specific plan before enrollment. Plans.healthcare.gov (the ACA marketplace) allows drug-level formulary checks during open enrollment. Off-exchange plans require checking each insurer's formulary directly.

ICHRA Contribution Limits and Rezdiffra Cost Exposure

The IRS has not capped ICHRA reimbursements for large employers. For 2026, small employers (fewer than 50 full-time equivalents) using ICHRA are subject to HRA rules under IRS Notice 2013-54 [9]. If the ICHRA allowance is $500/month and Rezdiffra's net cost after copay assistance is $0, $50/month (see Madrigal Savings Program below), the ICHRA allowance easily covers premiums plus drug costs for most patients.

Pairing ICHRA With the Madrigal Savings Program

The most cost-effective path for ICHRA enrollees in 2026 is:

1. Select an individual market plan (Silver or Gold tier) that includes Rezdiffra on its specialty formulary.
2. Enroll in Madrigal's Rezdiffra Savings Program (commercially insured patients may pay as little as $0/month with a maximum benefit of $25,000/year per the program terms).
3. Submit monthly insurance premiums for ICHRA reimbursement.
4. Any remaining Rezdiffra out-of-pocket after the copay card applies may also be submitted to ICHRA as a qualified medical expense if the employer's ICHRA plan design allows it.

This framework reduces total annual patient cost to the premium co-contribution, often under $2,000/year, for patients who select the right plan.

Madrigal's Patient Support Programs

Madrigal Pharmaceuticals operates a hub program called Rezdiffra One Source. It provides benefits investigation, PA support, appeal assistance, and financial assistance enrollment [10].

Rezdiffra Savings Program (Commercial Insurance)

Eligible patients with commercial (employer or individual market) insurance can pay as little as $0 per month. The program has a stated annual maximum benefit of $25,000. Patients who have already met their deductible and face a coinsurance bill use the card to cover that coinsurance up to the annual cap. Income eligibility criteria are not required for the commercial copay card, but the patient must have commercial insurance (Medicare, Medicaid, and other federal programs are excluded) [10].

Patient Assistance Program (Uninsured or Underinsured)

For uninsured patients or those who do not qualify for the copay card, Madrigal offers a Patient Assistance Program (PAP) providing Rezdiffra at no cost. Income thresholds apply and are updated annually. Enrollment goes through Rezdiffra One Source [10].

Specialty Pharmacy Coordination

Once PA is approved, Rezdiffra One Source coordinates the transfer to the dispensing specialty pharmacy. The specialty pharmacy contacts the patient to verify shipping address, obtain copay card information, and schedule delivery. Refill reminders are typically automated at 30-day intervals.

HSA and FSA Eligibility for Rezdiffra

Rezdiffra purchased with a valid prescription qualifies as a medical expense under IRS Section 213(d), making it eligible for reimbursement through both Health Savings Accounts (HSAs) and Flexible Spending Accounts (FSAs) [8].

HSA Compatibility

HSA funds can be used tax-free for prescription drug costs, including specialty medications like Rezdiffra, provided the account holder is enrolled in a qualifying High Deductible Health Plan (HDHP). The 2026 HSA contribution limits are $4,300 (individual) and $8,550 (family) per IRS Publication 969 [11]. Because most HDHP deductibles are $1,600, $3,200, and Rezdiffra's copay card typically reduces patient cost to near $0 for commercially insured patients, HSA use is primarily relevant for patients paying full deductible costs before the copay card activates.

FSA Compatibility

FSA funds also cover prescription Rezdiffra costs under the same IRS Section 213(d) rules [8]. The 2026 FSA contribution limit is $3,300 per IRS Rev. Proc. 2025-29. Unlike HSAs, FSAs are not tied to HDHP enrollment, so patients on any employer plan type can use FSA dollars for drug costs not covered by the copay card.

Practical HSA/FSA Strategy

Pay the specialty pharmacy invoice with your HSA/FSA debit card or submit for reimbursement after paying out-of-pocket. Keep the pharmacy receipt and the prescription label as documentation. If you have both a copay card and an FSA, apply the copay card first. Any remaining balance is then FSA-eligible.

Handling Denials and Appeals

Coverage denials are common on first submission, particularly for drugs in new therapeutic categories. The MASH therapeutic space has no direct comparators, which is an advantage in appeals [3].

Internal Appeal

File within the plan's appeal window (typically 180 days for adverse benefit determinations under ACA rules). Include the MAESTRO-NASH NEJM publication [3], the FDA approval letter [1], AASLD guidance [6], and your prescriber's clinical narrative. Ask your hepatologist to write a letter of medical necessity citing the specific fibrosis stage and the absence of approved alternatives.

External Review

If the internal appeal fails for ERISA plans, request an independent external review through your state insurance commissioner or the federal ERISA external review process. External reviewers reverse denials at meaningful rates when the denied drug is the only FDA-approved option for the indication. The Affordable Care Act mandates this right for most plans [5].

Expedited Review

For patients with F3 fibrosis approaching cirrhotic transition, expedited internal and external review (72 hours) is available under ACA rules when the standard timeline would seriously jeopardize health [5].

Clinical Context: Why Fibrosis Stage Documentation Matters

Payers and appeals reviewers are not hepatologists. Clear, unambiguous fibrosis staging documentation is the single greatest predictor of PA and appeal success.

Noninvasive Testing Standards

Liver biopsy remains the gold standard but is invasive. For PA purposes, most payers now accept validated noninvasive tests. The NIH-supported NASH Clinical Research Network uses FibroScan liver stiffness measurement (LSM) with a cutoff of ≥8.2 kPa for F2 and ≥9.7 kPa for F3 [12]. The FIB-4 index (age × AST / (platelet count × √ALT)) with values above 1.30 warrants further evaluation per AASLD guidance [6].

Linking Fibrosis Stage to the FDA Label

The FDA label for Rezdiffra specifies: "the presence of moderate-to-advanced liver fibrosis (consistent with stages F2 to F3)" [1]. If your diagnostic report uses different staging language (e.g., Metavir vs. Ishak), include a conversion note in the PA submission clarifying equivalence. This prevents payer confusion and reduces the chance of a technicality denial.

MAESTRO-NASH Entry Criteria as a PA Template

MAESTRO-NASH enrolled adults with MASH (confirmed by biopsy), NAS score ≥4, and fibrosis stage F1B, F2, or F3. The FDA approved only the F2, F3 subgroup for commercialization [3]. Confirming your patient meets these parameters before submission avoids the most common PA rejection reason: insufficient fibrosis severity documentation.